Stock A314130 GENOME & COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Genome & Company

Equities

A314130

KR7314130006

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
7,120 KRW -0.84% Intraday chart for Genome & Company +3.04% -42.99%
01-24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
2023 Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A314130 Stock
  4. News Genome & Company
  5. Other languages